How to Get Retatrutide: Clinical Trials, Access, and Availability

The Short Answer

Retatrutide is not approved by the FDA or any other regulatory authority in the world. It is not legally available for prescription, dispensing, or sale in any country. The only legitimate way to receive retatrutide is through enrollment in an authorized clinical trial sponsored by Eli Lilly.

Based on Eli Lilly’s Q4 2025 earnings guidance (February 2026), the company expects to submit a New Drug Application (NDA) in late 2026. Assuming a standard FDA review period, the earliest realistic approval date is mid-2027, with late 2027 to early 2028 considered the more probable timeline. Commercial availability would follow shortly after approval — placing the earliest realistic date that patients could receive a prescription in 2028.

Until that time, clinical trial enrollment remains the only pathway to receiving pharmaceutical-grade retatrutide under medical supervision.

Current Regulatory Status (March 2026)

Retatrutide (LY3437943) is an investigational triple GIP/GLP-1/glucagon receptor agonist in Phase 3 clinical development. It has no brand name, no approved indication, and no regulatory marketing authorization anywhere in the world.

Where the TRIUMPH Program Stands

Eli Lilly’s Phase 3 program for retatrutide — known as TRIUMPH — is one of the largest metabolic drug development programs currently underway. The program encompasses multiple pivotal trials across obesity, type 2 diabetes, and metabolic liver disease:

• TRIUMPH-4 was the first trial to report results, releasing top-line data in December 2025. This 68-week study in 445 adults with obesity and knee osteoarthritis demonstrated -28.7% mean weight loss at the 12 mg dose and -26.4% at 9 mg (Eli Lilly press release, December 2025). These represent the largest weight loss figures ever reported for any drug in a Phase 3 trial.
• Six or more additional Phase 3 readouts are expected throughout 2026, including results from TRIUMPH-1 (the primary obesity pivotal trial), TRIUMPH-2, TRIUMPH-3, and the TRANSCEND diabetes program.
• Eli Lilly plans to submit an NDA in late 2026, based on Q4 2025 earnings guidance. The company has indicated it will initially file for obesity, obstructive sleep apnea, and osteoarthritis of the knee.

Key TRIUMPH-4 Data Points

The TRIUMPH-4 results established retatrutide’s Phase 3 efficacy profile:

• 12 mg dose: -28.7% mean body weight loss at 68 weeks
• 9 mg dose: -26.4% mean body weight loss at 68 weeks
• 99% of participants at 12 mg achieved at least 5% weight loss
• 74.3% reduction in knee osteoarthritis pain at 12 mg (75.8% at 9 mg) (WOMAC pain score)
• Dose escalation protocol: 2 mg → 4 mg → 6 mg → 9 mg → 12 mg
• Notable adverse events: dysesthesia (numbness, tingling, burning) in 20.9% at 12 mg and 8.8% at 9 mg versus 0.7% with placebo; nausea in 43.2% and diarrhea in 33.1% at 12 mg

These results are highly encouraging, but a single Phase 3 trial is not sufficient for regulatory approval. Multiple additional data readouts are required before Eli Lilly can file its NDA.

Clinical Trial Enrollment: The Only Legitimate Access Pathway

For individuals who are interested in receiving retatrutide before it reaches the market, enrollment in an authorized clinical trial is the only option that provides a properly manufactured drug product under medical supervision with appropriate safety monitoring.

Active Clinical Trials

The following trials are part of the retatrutide Phase 3 program. Note that many of these trials are in late stages of enrollment or fully enrolled as of March 2026. Enrollment status changes frequently, and the information below should be verified on ClinicalTrials.gov:

General Eligibility Criteria

While specific criteria vary by trial, the TRIUMPH obesity trials generally require:

• Age: Adults 18 years and older (some trials 18-75)
• BMI: ≥30 kg/m2, or ≥27 kg/m2 with at least one weight-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, obstructive sleep apnea, or osteoarthritis)
• Exclusion criteria typically include: type 1 diabetes, recent cardiovascular events, bariatric surgery within 12 months, current use of other anti-obesity medications, pregnancy or planning pregnancy, and certain endocrine disorders

For the TRANSCEND diabetes trials, participants must have a confirmed diagnosis of type 2 diabetes with HbA1c within a specified range and be on stable background diabetes therapy.

How to Explore Trial Enrollment

1. Search ClinicalTrials.gov for “retatrutide” or “LY3437943” to view all registered trials, their status, eligibility criteria, and participating sites.
2. Discuss with your physician. Your healthcare provider can assess whether you meet likely eligibility criteria and refer you to a participating site. Physician referral is often the most efficient pathway to enrollment.
3. Contact study sites directly. Each trial listing on ClinicalTrials.gov includes contact information for recruiting sites. Sites can confirm whether the trial is still enrolling and schedule a screening visit.
4. Understand the commitment. Clinical trial participation involves regular clinic visits (often monthly), the possibility of receiving placebo rather than active drug, strict visit schedules, laboratory monitoring, and treatment durations of 68 weeks or longer. Participants also contribute valuable data to the scientific understanding of retatrutide.

Important Enrollment Considerations

Most TRIUMPH trials initiated enrollment in 2024, and several are approaching or have reached their target enrollment numbers. TRIUMPH-4 has completed enrollment and data collection. For the remaining trials, available slots may be limited, and geographic access varies by site location.

Clinical trial participation is voluntary, and withdrawal is permitted at any time. Participants receive the study drug and medical monitoring at no cost but do not receive financial compensation for the drug itself.

When Will Retatrutide Be Available?

The following timeline reflects current estimates based on Eli Lilly’s public statements, the TRIUMPH program’s progress, and standard FDA review timelines. All dates are approximate and subject to change.

Factors That Could Affect This Timeline

• Accelerating factors: Priority Review designation (reduces review to 6 months), rolling NDA submission, strong safety data across all trials, Breakthrough Therapy designation
• Delaying factors: FDA requests for additional data, safety signals requiring further characterization (such as the dysesthesia finding), manufacturing scale-up issues, Advisory Committee review requirements, or delays in completing the remaining Phase 3 trials

The dysesthesia signal observed in TRIUMPH-4 — affecting 20.9% of participants at the 12 mg dose — represents a finding that the FDA will scrutinize carefully. How this adverse event manifests across the broader TRIUMPH program will be a factor in the review timeline and potentially in labeling decisions.

Compounding Pharmacies: A Legal Gray Area

The compounding pharmacy landscape for GLP-1 receptor agonists has generated significant public attention. However, the legal and regulatory framework for compounding retatrutide is fundamentally different from the situation with semaglutide or tirzepatide.

Why Compounded Retatrutide Has No Legal Basis

Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may produce copies of commercially available drugs under specific circumstances — most notably when the FDA has listed the drug as being in shortage. This is the legal framework under which some compounding pharmacies have produced semaglutide and tirzepatide during documented shortage periods.

Retatrutide does not meet any of these criteria:

• It is not an approved drug. There is no FDA-approved version of retatrutide that a compounding pharmacy could be replicating.
• It is not in shortage. A drug that does not exist on the commercial market cannot be in shortage.
• There is no USP monograph or approved reference standard for compounding pharmacies to follow for retatrutide.
• Eli Lilly holds active patents on retatrutide and has demonstrated willingness to pursue legal action against unauthorized production of its compounds.

FDA Enforcement Actions

The FDA has taken an increasingly active role in regulating compounded GLP-1 products. The agency has issued warning letters to compounding pharmacies, pursued injunctions, and worked with state pharmacy boards to enforce compliance. These enforcement actions have focused on semaglutide and tirzepatide compounders, but the regulatory principles apply equally — and more clearly — to retatrutide, where there is no shortage exemption to argue.

Any pharmacy claiming to compound retatrutide is operating without a recognized legal framework and exposing both itself and its customers to regulatory and safety risk.

The Unverified Supplier Problem

The growing interest in retatrutide has led to a proliferation of online vendors selling products labeled as retatrutide. These products are typically marketed as “research peptides” with disclaimers stating they are “not for human consumption.” The vast majority of these suppliers operate without any independent quality verification.

Why Quality Verification Matters

The core issue is not the existence of research peptide suppliers — it is the absence of quality standards. Without independent verification, there is no way for a buyer to assess what they are actually receiving. The specific risks of unverified products include:

• Unknown purity and identity. Independent analyses of unverified peptide products have repeatedly found wrong compounds, wrong concentrations, or significant impurities. Without third-party lab testing and certificates of analysis (COAs) from accredited laboratories, there is no assurance that a product contains what it claims.
• No sterility assurance. Injectable products require rigorous sterility testing and manufacturing controls. Suppliers without validated sterility processes create risk of bacterial contamination, endotoxin contamination, and injection site infections.
• Degradation from improper handling. Peptide drugs are sensitive to temperature, light, and handling. Without documented cold-chain logistics and stability testing, degradation can render the product ineffective or produce harmful breakdown products.
• Incorrect concentrations. Without validated assay testing, the actual amount of peptide per vial may differ substantially from the label claim. This makes accurate dosing impossible.
• No batch traceability. Verified pharmaceutical manufacturing requires full batch documentation. Without it, there is no way to trace quality issues or recalls back to their source.

Why Medical Oversight Matters Regardless of Source

Even a product that contains genuine retatrutide at the correct concentration requires medical supervision. The TRIUMPH-4 data illustrate why:

• Dysesthesia occurred in 20.9% of participants at 12 mg and 8.8% at 9 mg (versus 0.7% on placebo). This neurological adverse event — characterized by numbness, tingling, or burning sensations — requires clinical assessment to distinguish from other neurological conditions and to determine whether dose modification is necessary.
• Gastrointestinal adverse events were common: nausea occurred in 43.2% and diarrhea in 33.1% of participants at the 12 mg dose. These effects can lead to dehydration, electrolyte imbalances, and nutritional deficiencies without appropriate management.
• The dose escalation protocol (2 mg → 4 mg → 6 mg → 9 mg → 12 mg) exists specifically to manage tolerability. Skipping escalation steps or escalating too quickly increases the severity of adverse events.
• Metabolic monitoring is essential for a triple receptor agonist that affects glucose metabolism, lipid metabolism, and cardiovascular parameters. Hypoglycemia, changes in heart rate, and effects on hepatic function require laboratory assessment.

Regulatory Context

The FDA has issued warning letters to multiple peptide vendors selling unapproved drug products, including those marketed as GLP-1 receptor agonists. These enforcement actions reflect the agency’s position that selling unapproved peptides for human use — regardless of “research use only” disclaimers — falls outside the regulatory framework. This regulatory reality makes independent quality verification even more critical, since unregulated products are not subject to the manufacturing inspections, batch testing, or recall mechanisms that apply to approved pharmaceuticals.

Approved Alternatives Available Now

Patients seeking effective weight management do not need to wait for retatrutide. Several FDA-approved anti-obesity medications are available today by prescription, with well-established safety profiles and demonstrated long-term efficacy:

Currently Approved Options

• Semaglutide (Wegovy) — A GLP-1 receptor agonist approved for chronic weight management. Phase 3 trials demonstrated approximately 15% mean weight loss at 68 weeks. Also approved to reduce cardiovascular risk in adults with obesity (SELECT trial). Weekly subcutaneous injection.
• Tirzepatide (Zepbound) — A dual GIP/GLP-1 receptor agonist approved for chronic weight management. Phase 3 SURMOUNT trials demonstrated approximately 22.5% mean weight loss at the highest dose over 72 weeks. Weekly subcutaneous injection. Also marketed as Mounjaro for type 2 diabetes.
• Liraglutide (Saxenda) — A GLP-1 receptor agonist approved for chronic weight management. Phase 3 trials demonstrated approximately 8% mean weight loss. Daily subcutaneous injection.
• Orlistat (Xenical/Alli) — A lipase inhibitor that reduces dietary fat absorption. Available by prescription (Xenical) and over-the-counter (Alli). Modest weight loss of approximately 3-5%.

Talking to Your Doctor

A healthcare provider can evaluate your individual medical history, comorbidities, contraindications, and treatment goals to recommend the most appropriate option among currently available therapies. The weight loss achieved with tirzepatide (Zepbound) — approximately 22.5% — represents a substantial therapeutic advance and may be appropriate for many patients who might otherwise consider waiting for retatrutide.

For patients with type 2 diabetes, both semaglutide (Ozempic) and tirzepatide (Mounjaro) are approved with strong glycemic efficacy data and cardiovascular benefits.

Comprehensive weight management also includes behavioral modification, dietary counseling, physical activity, and in some cases, bariatric surgery. These approaches can be pursued alongside or independent of pharmacotherapy.

Frequently Asked Questions

Can I obtain retatrutide online?

Retatrutide is not approved by any regulatory authority and cannot be legally prescribed or dispensed. Products sold online as “retatrutide” are not manufactured under GMP conditions and carry significant risks related to purity, sterility, potency, and contamination unless independently verified by third-party laboratory testing. The FDA has issued warning letters to vendors selling unapproved peptide products. For pharmaceutical-grade retatrutide under medical supervision, authorized clinical trials remain the only pathway.

Is retatrutide available in the UK, Europe, or other countries?

No. Retatrutide is not approved or available anywhere in the world as of March 2026. It is an investigational compound in Phase 3 development. International regulatory submissions (EMA, MHRA, and others) are expected to follow the initial US FDA filing. European approval would likely come 6-12 months after FDA approval, placing realistic European availability in 2028-2029 at the earliest.

How do I join a retatrutide clinical trial?

Search ClinicalTrials.gov for “retatrutide” or “LY3437943” to view all registered trials. Each listing includes eligibility criteria, study locations, and contact information. Discuss potential participation with your physician, who can assess whether you meet likely eligibility requirements and provide a referral. Be aware that many TRIUMPH trials are in late-stage enrollment as of March 2026, and available slots may be limited.

When will retatrutide receive FDA approval?

Based on Eli Lilly’s Q4 2025 earnings guidance, the company plans to submit an NDA in late 2026. Assuming FDA acceptance and a standard 10-month review, approval could come in late 2027. If granted Priority Review (6-month review), approval could come as early as mid-2027. The most likely window is late 2027 to early 2028. Commercial availability would follow shortly after approval, realistically placing prescription access in 2028.

Is retatrutide the same as tirzepatide (Mounjaro/Zepbound)?

No. While both are incretin-based peptide therapies developed by Eli Lilly, they are distinct molecules with different receptor activity profiles. Tirzepatide is a dual GIP/GLP-1 receptor agonist that is FDA-approved and commercially available as Mounjaro (type 2 diabetes) and Zepbound (obesity). Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist — the addition of glucagon receptor activity differentiates it from tirzepatide and may contribute to its greater weight loss efficacy, as well as its distinct adverse event profile, including the dysesthesia signal.

What is the difference between research peptides and clinical-grade drugs?

The difference is fundamental. Clinical-grade pharmaceutical products are manufactured under stringent Good Manufacturing Practice (GMP) conditions with validated processes, tested for identity, purity, potency, sterility, and endotoxin content, and subject to regulatory oversight from the FDA or equivalent agencies. Every batch is documented, traceable, and held to defined specifications. “Research peptides” sold online are manufactured without GMP oversight, without regulatory inspection, without validated sterility or potency testing, and without any accountability for quality or safety. Independent testing of gray-market peptides has consistently revealed problems with identity, purity, and contamination. For an injectable drug, these differences carry direct implications for patient safety.

Summary

Retatrutide is not approved or commercially available as of March 2026. The TRIUMPH Phase 3 program is progressing, with TRIUMPH-4 reporting -28.7% mean weight loss at 12 mg over 68 weeks — the largest ever in a Phase 3 obesity trial. Eli Lilly plans to submit an NDA in late 2026, with FDA approval most likely in late 2027 to early 2028 and commercial availability in 2028. For pharmaceutical-grade retatrutide under medical supervision, clinical trial enrollment is the established pathway. For those considering other sources, independent quality verification — including third-party lab testing, COAs from accredited laboratories, and documented cold-chain handling — is essential to assessing product integrity. Patients seeking effective weight management today should also consult their healthcare provider about FDA-approved options including semaglutide (Wegovy) and tirzepatide (Zepbound).